Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA ...
Fierce Biotech

Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits

After mulling its options for the past few months, Protagonist Therapeutics has decided to pocket $475 million from Takeda ...

Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc.

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on ...
Benzinga.com

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...